This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:starting:physician:reluctant [03.29.2017] – [Be firm] sallieq | home:starting:physician:reluctant [04.15.2019] – [Specific research] sallieq | ||
---|---|---|---|
Line 160: | Line 160: | ||
// | // | ||
+ | |||
+ | ==== Ascertain if reluctance is a provider problem or a bureaucracy problem ==== | ||
+ | |||
+ | In Australia, physicians must now approach Canberra (federal bureaucracy) for permission to prescribe off-label. | ||
+ | |||
+ | < | ||
+ | |||
+ | He simply smiled and wrote me 2 prescriptions: | ||
+ | |||
+ | I expect some other countries also have centralised control, in which case patients may need to research | ||
+ | |||
+ | === Specific research === | ||
+ | |||
+ | |||
+ | [[home: | ||
+ | |||
+ | OLM refs to print; | ||
+ | including information about dose relating to body weight, and dose timing | ||
+ | |||
+ | |||
+ | Dose timing -> | ||
+ | {{ : | ||
+ | |||
+ | {{ : | ||
+ | |||
+ | The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed> | ||
+ | |||
+ | short extract for each research study follows: | ||
+ | |||
+ | |||
+ | Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued. (({{pubmed> | ||
+ | |||
+ | |||
+ | Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (3 mg/kg) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat)(({{pubmed> | ||
+ | |||
+ | Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pubmed> | ||
+ | |||
+ | Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity & apoptosis induction against tumour cells in breast cancer (({{pubmed> | ||
+ | 10) | ||
+ | |||
+ | Alzheimer' | ||
+ | |||
+ | |||
+ | prevent migraines (({{pubmed> | ||
+ | |||
+ | |||
+ | inhibit liver fibrosis and aid liver healing (({{pubmed> | ||
+ | |||
+ | |||
+ | 6 mg/kg olmesartan reduces the inflammatory process and bone loss in rats (({{pubmed> | ||
+ | |||
+ | |||
+ | protect the mitochondria from age-associated damage from oxidation (({{pubmed> | ||
+ | |||
+ | |||
+ | reduce liver fibrosis (({{pubmed> | ||
+ | |||
+ | |||
+ | treatment of anxiety and stress-related disorders (({{pubmed> | ||
+ | |||
+ | |||
+ | inflammation in myocarditis (({{pubmed> | ||
+ | |||
+ | |||
+ | C-reactive protein, one of the acute phase proteins that increase during systemic inflammation (({{pubmed> | ||
+ | |||
+ | |||
+ | cytokine damage (({{pubmed> | ||
+ | |||
+ | in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, | ||
+ | |||
+ | renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed> | ||
+ | |||
+ | olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects (({{pubmed> | ||
+ | |||
+ | |||
+ | * treatment with olmesartan inhibited bone loss (({{pubmed> | ||
+ | |||
+ | |||
+ | * olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed> | ||
+ | |||
+ | |||
+ | * decreases viability of malignant cell lines(({{pubmed> | ||
+ | |||
+ | |||
+ | * carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques (({{pubmed> | ||
+ | |||
+ | |||
+ | * improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed> | ||
+ | |||
+ | |||
+ | * improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed> | ||
+ | |||
+ | |||
+ | * OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed> | ||
+ | |||
+ | |||
+ | * prevention of microalbuminuria in patients with type 2 diabetes and hypertension (({{pubmed> | ||
+ | |||
+ | |||
+ | Recent studies showed treatment with olmesartan inhibited bone loss (({{pubmed> | ||
+ | |||
+ | |||
+ | olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed> | ||
+ | |||
+ | |||
+ | decreases viability of malignant cell lines (({{pubmed> | ||
+ | |||
+ | |||
+ | carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced | ||
+ | the volume of larger atherosclerotic plaques (({{pubmed> | ||
+ | |||
+ | |||
+ | improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed> | ||
+ | |||
+ | |||
+ | improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed> | ||
+ | |||
+ | |||
+ | OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed> | ||
+ | |||
+ | |||
+ | Long term treatment Data suggest 40 & 80 mg olmesartan are able to significantly remodel & destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg. hyper.ahajournals.org/ | ||
+ | |||
===== Read more ===== | ===== Read more ===== | ||
Line 168: | Line 292: | ||
* [[http:// | * [[http:// | ||
+ | {{section>: | ||
{{tag> | {{tag> |